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Abstract
This article will review how epidemiological studies have advanced
our knowledge of both genetic and environmental risk factors for
rheumatic diseases over the past decade. The major rheumatic
diseases, including rheumatoid arthritis, juvenile idiopathic arthritis,
psoriatic arthritis, ankylosing spondylitis, systemic lupus erythema-
tosus, scleroderma, osteoarthritis, gout, and fibromyalgia, and
chronic widespread pain, will be covered. Advances discussed will
include how a number of large prospective studies have improved
our knowledge of risk factors, including diet, obesity, hormones,
and smoking. The change from small-scale association studies to
genome-wide association studies using gene chips to reveal new
genetic risk factors will also be reviewed.
Introduction
This article will review epidemiological studies that have
advanced the knowledge of both genetic and environmental
risk factors for the rheumatic diseases, outlining the major
advances that have been achieved over the past decade
(Table 1). It will focus on the following diseases: rheumatoid
arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis
(PsA), ankylosing spondylitis (AS), systemic lupus erythema-
tosus (SLE), scleroderma (Scl), osteoarthritis (OA), gout, and
fibromyalgia (FM) and chronic widespread pain (CWP).
A number of large prospective studies have improved our
knowledge of risk factors: the Framingham Study [1] and the
Chingford 1000 Women Study [2] for OA, the Nurses’
Health Study cohort for RA [3] and SLE [4], the European
Prospective Investigation of Cancer in Norfolk (EPIC-Norfolk)
for inflammatory polyarthritis [5], and the Health Professionals
Follow-up Study for gout [6]. These types of studies provide
valuable and robust information. Unfortunately, epidemio-
logical data often are obtained from retrospective studies and
underpowered case-control studies, resulting in contradictory
findings (for example, studies on the role of caffeine in RA).
Although some of the studies have found significant associa-
tions with novel risk factors, these studies often suffer from
poor design. Meta-analyses have also been performed in an
attempt to form conclusions from the available epidemio-
logical data and these are also discussed.
Over the past decade, genetic research has moved from the
approach of small-scale association studies, to test for candi-
date genes in case-control studies, to whole-genome scans
of linkage based on sibling pairs which proved to be limited in
the small numbers of both pairs and markers (both in the
hundreds). The more recent and exciting approach has been
genome-wide association studies using gene chips which
have allowed hundreds of thousands of single-nucleotide
polymorphisms (SNPs) to be investigated as exemplified by
the Wellcome Trust Case-Control Consortium (WTCCC)
study of common diseases (including RA) [7]. The advantage
to this approach is clearly the opportunity to identify novel
genes for the diseases; however, the disadvantage is that it
results in large numbers of hints that require verification in
further studies to validate the results.
In general, the studies discussed in this review identify risk
factors in whole populations of patients with the disease but
it is more likely that each of the individual disease phenotypes
results from a number of different combinations of genetic
and environmental risk factors. Thus, some risk factors may
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Table 1
Risk factors for the major rheumatic diseases over the past 10 years
Disease  Host/Environmental risk factor  Gene
Rheumatoid arthritis Diet (caffeine and Mediterranean diet) PTPN22
Smoking PADI4
Hormones  CTLA4
FCRL3
MHC2A
HLA DRB1
Juvenile idiopathic arthritis Macrophage inhibitory factor (MIF)
PTPN22
NRAMP1
IL-6
Psoriatic arthritis  Rubella vaccination CARD15
Injury requiring medical consultation MICA
Recurrent oral ulcers TNF
Moving house IL
Corticosteroids
Pregnancy
Ankylosing spondylitis ARTS1
IL-23R
IL-1 gene cluster
Cytochrome P450 2D6 (CYP2D6) gene
Systemic lupus erythematosus  Breast-feeding MHC
Early natural menopause ITGAM
Lipstick  IRF5
BLK
STAT4
PTPN22
FCGR2A
Scleroderma  Exposure to silica or organic solvents Familial risk
HLA-DQA1
Fibrillin-1 SNP haplotypes
TGF-β
CTGF
Foetal microchimerism
Osteoarthritis  Obesity/Body mass index IL-1 gene cluster
Physical activity Frizzled-related protein-3 (FRZB) gene
Grip strength Matrilin-3 gene
Previous injury IL-4 receptor
Metalloproteinase gene ADAM12
Asporin (ASPN) gene
Estrogen receptor
Gout  High purine diet TNF-α promoter
Dairy products
Hypertension
Pharmacologic agents
Fibromyalgia and chronic  Physical trauma Serotonin transporter gene
widespread pain  Somatisation Familial risk
Health-seeking behaviour COMT
Poor sleep 
ADAM12, a disintegrin and metalloproteinase domain 12; ARTS1, type 1 tumor necrosis factor receptor shedding aminopeptidase regulator; BLK,
B lymphoid tyrosine kinase; CARD15, caspase recruitment domain 15; COMT, catechol-O-methyltransferase; CTGF, connective tissue growth
factor; CTLA4, cytotoxic T lymphocyte-associated antigen-4; FCGR2A, Fc fragment of IgG, low-affinity IIA, receptor (CD32); FCRL3, Fc-receptor
like-3; IL, interleukin; IRF5, interferon regulatory factor 5; ITGAM, integrin, alpha M; MHC, major histocompatibility complex; MHC2A, major
histocompatibility complex 2A; MICA, class I major histocompatibility complex chain-related gene A; NRAMP1, natural-resistance–associated
macrophage protein 1; PADI4, peptidyl arginine; PTPN22, protein tyrosine phosphatase; SNP, single-nucleotide polymorphism; STAT4, signal
transducer and activator of transcription 4; TGF-β, transforming growth factor-beta; TNF, tumour necrosis factor.have a strong effect but only in a small proportion of patients,
whereas others will have weak effects and be present in a
greater number of individuals but require the involvement of
other risk factors. Thus, the size of any increased risk is not a
reflection of the level of its attribution to disease causation.
However, the sense of strength of risk in this review has been
split arbitrarily into three groups based on the typically
reported strength of association: ‘small’ (odds ratio [OR] or
relative risk [RR] of less than 2), ‘moderate’ (OR or RR of
between 2 and 5), or ‘substantial’ (OR or RR of greater than
5).
Rheumatoid arthritis
Environmental risk factors
Studies of environmental risk factors in RA have focused on
diet, smoking, and hormones [8]. Several studies have investi-
gated consumption of coffee/tea/caffeine as a risk factor but
with mixed conclusions. Caffeine has been reported to
moderately increase the risk of rheumatoid factor (RF)-
positive RA, but no increased risk for RF-negative RA was
found [9]. Decaffeinated coffee has been associated with a
moderately increased risk of RA, whereas tea has been
shown to have a protective effect [10]. The authors suggest
that the decaffeination process (use of industrial solvents)
and small traces of solvents may play a role in the disease
whereas tea may have both anti-inflammatory and
antioxidative properties [10]. However, other studies have
found no association of caffeine/coffee consumption with RA
[3]. Clearly, studies that are more robust are needed to verify
these results.
The so-called ‘Mediterranean diet’ has been linked with health
benefits for a number of diseases and this is also true for RA
[11,12]. High consumption of olive oil, oil-rich fish, fruit and
vegetables [13], or vitamin D [14] has been shown to have a
protective role in the development of RA. High consumption
of red meat and meat products [5] has been associated with
a moderately increased risk of inflammatory polyarthritis, but
no risk was found in a more recent study [15].
Data on the link between smoking and RA are more com-
pelling and include recent studies implicating a gene-environ-
ment interaction (see below). The duration and intensity of
smoking have been linked to the development of RA in
postmenopausal women [16]. Current smokers and those
who had quit for 10 years or less were found to have a small
increased risk of RA, whereas those who had quit for more
than 10 years had no increased risk. Heavy cigarette smoking
has been linked with a substantial increased risk of RA [17]
(over 13-fold) and there was an increasing association
between increasing pack-years of smoking and RA. Current
smoking has been found to be a risk factor for RA, with the
risk moderately increased in men and more so in men with
seropositive RA [18]. Other studies have also shown a small
increased risk due to smoking for seropositive RA in both
women and men but have not shown an increased risk for
seronegative RA [19]. This risk was evident in subjects who
had long-term smoking habits (>20 years) and was evident
even if daily smoking intensity was only moderate. Duration of
smoking rather than intensity has also been found to be a risk
factor in a study of female health professionals [20]. Smoking
has also been linked with an increase in both the severity of
RA and disease activity [21,22], supporting a role for
smoking in the development of RA. Other host factors that
have been associated with RA include blood transfusion and
obesity [23] and (high) birth weight [24], which have been
linked with a moderate increased risk, and breast-feeding
[25] and alcohol [26], which have been linked with a
decreased risk/protective role. Stress has also been reported
to have a role in the development of RA [27].
Genetic risk factors
Genetic factors implicated in RA have been widely studied
using both candidate genes and whole-genome screens [28].
Whereas the strongest genetic risk factor for RA remains the
HLA DRB1 shared epitope (SE), other candidate genes have
been consistently implicated. In particular, an SNP (R620W)
in the protein tyrosine phosphatase (PTPN22) gene, which
has regulatory activities for both T and B cells, has been
associated with RA [29]; furthermore, this has been
replicated in well-powered studies in different populations
[30-33]. This polymorphism has been associated with other
autoimmune diseases, including JIA and SLE [28]. Studies on
peptidyl arginine (PADI4) have shown a significant
association [34] but so far this has been replicated in one
other Japanese study [35] only and not in populations from
the UK [36], France [37], or Spain [38]. A recent meta-
analysis of three Asian and six European studies has shown
that  PADI4 polymorphisms were associated with Asian
populations; in European populations, only PADI4_94 had a
significant association [39]. Genes such as CTLA4, FCRL3,
and major histocompatibility complex 2A (MHC2A) have also
been the focus of recent research [28].
The search for novel genes has been advanced by the
powerful approach of genome-wide association studies as
typified by the UK WTCCC. This has identified three genes
with independent associations for RA: two that have been
reported to have strong associations (HLA-DRB1 and
PTPN22) and a further one on chromosome 7 that had
different genetic effects between genders with a strong and
apparently additive effect on disease status in females [7].
Further susceptibility loci are likely to be discovered using
this approach. Similarly, alleles from 14 genes from over
2,300 cases and 1,700 controls from the North American
Rheumatoid Arthritis Consortium (NARAC) (the US version of
the WTCCC) and the Swedish Epidemiological Investigation
of Rheumatoid Arthritis (EIRA) collections have supported
evidence for association of RA with PTPN22, CTLA4, and
PADI4 (NARAC cohort only) [40]. There is also evidence that
there is a genetic overlap with other autoimmune diseases
(SLE, AS, multiple sclerosis, and inflammatory bowel disease)
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research focuses on evidence that certain polymorphisms
can predict the response of a patient to treatment [42] and
this is likely to be the focus of a number of future studies.
Gene-environment interactions
One of the most interesting studies has shown evidence of
an important gene-environment interaction between the SE
and smoking [43]. This Swedish population-based case-
control study showed that the risk of developing RF-positive
RA substantially increased in smokers carrying double copies
of SE genes (RR = 15.7) compared with smokers with no
copies of SE genes (RR = 2.4). Recent research has also
shown additive and multiplicative interactions between
PTPN22 and heavy cigarette smoking [44]. It has also been
proposed that risk factors such as smoking, alcohol and
coffee consumption, obesity, and oral contraceptive use may
depend on the presence or absence of autoantibodies to
cyclic citrullinated peptides [45,46].
Juvenile idiopathic arthritis
Epidemiological studies of JIA have been hampered by a lack
of standardised criteria and case ascertainment, resulting in
wide-ranging results: reported prevalence ranges from 0.07
to 4.01 per 1,000 children, and annual incidence varies from
0.008 to 0.226 per 1,000 children [47]. Hopefully, the
development of new diagnostic criteria will aid future studies
in having results that are more consistent. Ethnicity has been
studied and European descent has been associated with a
moderately increased risk of JIA; additionally, JIA subtypes
differed significantly between ethnic groups [48]. There have
been few developments in terms of environmental risk factors,
although infection remains the most favoured hypothesis.
Genetic risk factors
Major advances in epidemiological studies of JIA have
focused mainly on genetic aspects. A genome-wide scan in
121 families (247 affected children) confirmed linkage of
juvenile RA to the HLA region [49]. In addition, early-onset
polyarticular disease has been linked to chromosome 7q11
and pauciarticular disease has been linked to chromosome
19p13, suggesting that multiple genes are involved in the
susceptibility to juvenile RA. Other candidate genes, inclu-
ding polymorphisms in the migration inhibitory factor (MIF)
gene, have been associated with JIA. A study of UK JIA
patients showed that patients with an MIF-173*C allele had a
small increased risk of JIA [50], and serum MIF levels were
also higher in patients with this allele. An SNP in the PTPN22
gene (a gene associated with both RA and SLE) has also
been shown to have a novel association with JIA [30]. A
recent meta-analysis has confirmed that the T allele and the
T/T genotype of PTPN22 C1858T are associated with JIA
[51]. Polymorphisms in the NRAMP1 gene may also play a
role in the pathogenesis of JIA [52]. There is some evidence
that a potentially protective CC genotype of the interleukin-6
(IL-6) gene is reduced in young patients [53].
Psoriatic arthritis
Epidemiologically, PsA is a complex disease to study as it is
not simple to disentangle whether the risk factors revealed
are for the complete disease phenotype of PsA or for one of
its two components. Studies that compare PsA with healthy
controls are not able to address this.
Environmental risk factors
Studies of environmental risk factors for PsA have focused on
infection-related triggers and hormones. In a recent case-
control study, exposure to rubella vaccination substantially
increased the risk of PsA whereas injury requiring medical
consultation, recurrent oral ulcers, and moving house all
moderately increased the risk of PsA [54]. The strongest
associations were with trauma, adding support to the
hypothesis of a ‘deep Koebner phenomenon’ in PsA. These
data suggest that infection-related triggers may be relevant
and further studies are required to verify these results. In a
nested case-control study, corticosteroid use (moderate
increased risk) and pregnancy (decreased risk) were both
associated with PsA, suggesting that changes to the immune
system may play a role in this disease [55].
Genetic risk factors
Developments in the pathogenesis of PsA again have been
mainly in the genetic field. There is evidence that caspase
recruitment domain 15 (CARD15), a susceptibility gene for
Crohn’s disease, has a role in PsA, and this is supported by
the fact that patients with Crohn’s disease have an increased
incidence of psoriasis. Initial reports suggested that over
38% of probands with PsA had at least one variant of the
CARD15 gene compared with 12% of controls [56]. This
pleiotropic autoimmune gene was proposed as the first non-
MHC gene to be associated with PsA. Unfortunately, this has
not been replicated in German [57] and Italian [58] cohorts;
in these cohorts, no such association was found. A novel
model that suggests that PsA susceptibility is determined by
the balance of activating and inhibitory composite killer Ig-like
receptor-HLA genotypes has been proposed [59]. Class I
MHC chain-related gene A (MICA) may confer additional
susceptibility to PsA. The MICA-A9 triplet repeat
polymorphisms were present at a substantially higher
frequency in PsA patients [60]. A linkage scan reported
evidence that suggests that a locus on chromosome 16q is
implicated in PsA; furthermore, the logarithm of the odds
(LOD) score is much higher for paternal transmission than
maternal transmission (4.19 and 1.03) [61]. Functional
cytokine gene polymorphisms have also been associated with
PsA [62], with tumour necrosis factor-alpha (TNF-α) –308
and TNF-β +252 polymorphisms being significantly asso-
ciated with age at psoriasis onset, presence of joint erosions
in PsA, and progression of joint erosions in early PsA. A
genome-wide association study recently replicated associa-
tions of PsA with IL-23 receptor and IL-12B polymorphisms
and also identified a novel locus on chromosome 4q27 [63].
A case-control study found evidence that HLA-Cw*06 and
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psoriasis in patients with PsA, suggesting that the primary
association is with age of onset of psoriasis [64].
Ankylosing spondylitis
Most of the epidemiological advances in AS have come from
the ascertainment of novel genetic associations. Few
environmental risk factors have been studied.
Genetic risk factors
Epidemiological studies have focused on the genetics behind
AS. Twin studies have estimated the influence of genetics on
the aetiopathogenesis of AS, indicating that additive genetic
effects account for 94% of the variance in the causation of
AS [65]. Genome-wide scans have confirmed the strong
linkage of the MHC with AS, which is not surprising given the
overwhelming relationship between HLA B27 and AS.
However, this study suggested that only 31% of the suscep-
tibility to AS is from genes in the MHC [66]. Thus, the search
for non-MHC genes has gained much interest [67]. One of
the most exciting developments has been the identification of
two new loci for AS from a major genetic association scan:
ARTS1 and IL-23R [68]. It was calculated from these studies
that these genes are responsible for 26% (ARTS1) and 9%
(IL-23R) of the population-attributable risk of AS. Another
strong non-MHC linkage lies on chromosome 16q (overall
LOD score of 4.7) [69]. Other scans have identified regions
on chromosomes 6q and 11q [70]. Combined analysis of
three whole-genome scans by the International Genetics of
Ankylosing Spondylitis Consortium showed that regions on
chromosomes 10q and 16q had evidence suggestive of
linkage. Other regions showing nominal linkage (in two or
more scans) were 1q, 3q, 5q, 6q, 9q, 17q, and 19q.
Evidence was also confirmed for regions previously asso-
ciated with AS on chromosomes 2q (the IL-1 gene cluster)
and 22q (cytochrome P450 2D6 [CYP2D6]) [71].
A linkage study of chromosome 22 in families with AS-
affected sibling pairs found that homozygosity for poor-
metaboliser alleles in the CYP2D6 (debrisoquine hydroxy-
lase) gene was associated with AS. The authors of that study
postulated that altered metabolism of a natural toxin or
antigen by this gene may increase the susceptibility to AS
[72]. AS has also been linked to the IL-1RN*2 allele [73] as
have other inflammatory diseases such as ulcerative colitis
and Crohn’s disease.
Systemic lupus erythematosus
Environmental risk factors
The majority of research into environmental risk factors for
SLE has focused on the role of hormones due to the higher
prevalence of this disease in women. In a recent population
case-control study, breast-feeding was found to be
associated with a reduced risk of SLE, with a trend for the
number of babies fed and total weeks of breast-feeding [74].
Women who developed SLE had an earlier natural
menopause whereas there was little association with current
use or duration of use of hormonal replacement therapy or
oral contraceptive pill and no association with the use of
fertility drugs. The authors of that study proposed that early
natural menopause may be a marker for susceptibility to SLE.
However, another study has shown that risk of SLE or discoid
lupus was moderately increased among current users of
estrogens who had exposure of at least 2 years [75]. A
prospective cohort study of women found no relationship
between oral contraceptive use, either with duration or time
since first use [4].
There has been a long-standing interest in the role of
chemical exposures causing SLE. An interesting association
has been found with lipstick use and SLE [76]. Researchers
found that using lipstick 3 days per week was significantly
associated with a small increased risk of SLE and this may be
worth replicating in future studies on environmental risk
factors. The authors suggest that chemicals (these include
eosin, 2-octynoic acid [a xenobiotic], and phthalate isomers)
present in lipsticks may be absorbed across the buccal
mucosa and have a biological effect on disease development.
Other risk factors associated with an increased risk of SLE
include history of hypertension, drug allergy, type I/II sun-
reactive skin type, and blood transfusions (all moderately
increasing the risk) and family history substantially increasing
the risk of SLE [77]. Consumption of alcohol has been
inversely associated with the risk of SLE [77]. A small
increased risk was found with smoking, but exposure to
estrogen or hair-colouring dyes, both of which previously
have been proposed as risk factors, was not associated.
Genetic risk factors
There has been a major increase in the understanding of the
genetics behind SLE, particularly over the last year, and this
topic is concisely summarised in a recent review [78]. Two
high-density case-control genome-wide association analyses
have been published [79,80]. From these studies, over-
whelming evidence for the association of various genes with
SLE (MHC,  ITGAM,  IRF5,  BLK, and STAT4 [79,80]) and
strong evidence for a role for PTPN22 and  FCGR2A
[51,79,81] have emerged. Other genes for which there is
evidence of an association, including the TNF superfamily
gene [82], in which the upstream region of TNFSF4 contains
a single risk haplotype for SLE, have also emerged. Gene
copy number variation may lead to variation in disease
susceptibility as highlighted in studies on the complement
component C4 in which patients with SLE had a lower gene
copy number of total C4 and C4A [83]. Zero copies or one
copy of the C4A gene increased the risk of disease
susceptibility, whereas three or more copies appeared to
have a protective role. The risk of SLE was substantially
greater in subjects with only two copies of total C4, but those
with five or more copies of C4 had a reduced risk of disease.
Another area of research focus has been on the role of sex
chromosomes in the development of SLE, especially given
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the increased incidence of Klinefelter’s syndrome (47, XXY)
in male patients with SLE, in whom the frequency was
substantially increased (14-fold) compared with men without
SLE, suggesting that the susceptibility to SLE could be due
to an X-chromosome gene-dose effect [84].
Scleroderma
Environmental risk factors
Epidemiological studies of Scl have focused on the role for
toxic environmental exposures. Specifically, studies have
carefully investigated silica and organic solvents as both are
thought to stimulate the immune system and cause inflamma-
tion and increase antibody production. Recent reports show
that occupational silica exposure moderately increases the
risk of Scl, with medium exposure increasing the risk twofold
and high exposure increasing the risk fourfold [85]. There is
still interest in the relationship of silicone breast implants and
Scl. However, a recent meta-analysis of nine cohorts, nine
case-control studies, and two cross-sectional studies found
no association with Scl or other connective tissue diseases
[86]. Exposure to organic solvents remains a moderate risk
factor and the presence of anti-Scl-70 autoantibodies may be
an effect modifier as the association was stronger in patients
with these antibodies [87]. However, such studies are
difficult to undertake as exposure to other chemicals cannot
be controlled.
Genetic risk factors
There is increasing evidence for a genetic role in Scl
development [88]. The familial risk of Scl has been
investigated in three large US cohorts with a significant
increase in risk observed: 2.6% in families with Scl compared
with 0.026% in the general public [89]. Studies of HLA
alleles suggest that the DQA1*0501 allele is significantly
increased in men with Scl compared with healthy men. This
allele was found to be moderately associated with diffuse Scl
in men but not with limited Scl [90]. HLA associations have
also been studied in mutually exclusive autoantibody
subgroups, lending support to the theory that Scl in
subgroups are actually separate diseases [91]. Transforming
growth factor-beta (TGF-β) and connective tissue growth
factor may have roles in Scl but further studies are required
[92,93]. Increased expression of TGF receptors may account
for the increased production of collagen type I by Scl fibro-
blasts [94]. Fibrillin-1 SNPs haplotypes have been strongly
associated with Scl in Choctaw and Japanese populations
[95]. Long-term foetal microchimerism is also still being
investigated as a potential risk factor [96,97].
Osteoarthritis
Environmental risk factors
Studies on environmental risk factors for OA have focused on
obesity, physical activity, and prior joint injury, all of which
may increase stress on the joints. There have been several
major cohort studies of OA, including the Framingham Study
[1], the Chingford 1000 Women Study [2], Bristol OA 500
[98], and the North Staffordshire Osteoarthritis Project
(NorSTOP) [99]. From these and other studies, a number of
risk factors, including high body mass index (BMI), previous
injury, and regular sports participation, have been found
[100,101]. The main preventable risk factor, and hence the
subject of many reports, is obesity, which has been shown to
substantially increase the risk of knee OA [100,102]. A
moderate influence of obesity has also been found with hip
OA [103]. Data from adult twins (St. Thomas’ Hospital Adult
Twin Registry) have shown a moderate association between
high BMI and knee OA (OR = 3.9) [104]. Manek and
colleagues, who gathered those data, also concluded that
this association was not influenced by shared genetic factors.
Other influences have been the effect of physical activity on
OA [105]. One study found a moderate association between
heavy physical workload and hip OA [106]. High levels of
physical activity were found to be a moderate risk factor for
OA of the knee/hip joints in men younger than 50 years [107].
Men with maximal grip strength have been found to have a
moderately increased risk of OA in the proximal inter-
phalangeal, metacarpophalangeal (MCP), and thumb base
joints, and women with maximal grip strength have been found
to have a moderately increased risk of OA in the MCP joints
[108]. There is some evidence that occupation can increase
the risk of hand OA. A recent case-control study showed that
occupations involving repetitive thumb use and jobs in which
there were perceived to be insufficient breaks were asso-
ciated with OA of the carpometacarpal (CMC) joints [109].
However, not all studies agree and a cross-sectional study
found no association with occupation, physical activity, or
sports participation but found a moderate increase in risk for
hand OA for self-reported digital fracture [110].
Genetic risk factors
Genetic studies in female twins have estimated that the
genetic contribution to radiographic hip OA is 58% for OA
overall and 64% for joint space narrowing [111]. Studies
have revealed that disease risk differs for males and females
at different sites and thus there may be specific genes rather
than a single OA phenotype [112]. The IL-1 gene cluster is a
key regulator in a number of chronic disease processes, and
within this cluster, haplotypes such as IL1A-IL1B-IL1RN,
which confers a moderate increase in the risk of OA, and
IL1B-IL1RN, which confers a fivefold reduced risk, have been
identified [113]. This cluster has also been proposed to
confer susceptibility for knee OA but not hip OA [114].
Functional polymorphisms in the frizzled motif associated with
bone development (FRZB) genes have been found to confer
susceptibility to hip OA in females [115]. Radiographic OA is
also associated with genotypes of the insulin-like growth
factor I gene [116].
Data from the Rotterdam study showed that polymorphisms
in the estrogen receptor-alpha (ESR1) gene are associated
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In a case-control study, several candidate genes were investi-
gated: the strongest associations with clinical knee OA were
found with a haplotype in ADAM12 (a disintegrin and metallo-
proteinase domain 12) and ESR1 in women [118] and again
with ADAM12 in men along with the CILP (cartilage
intermediate layer protein) haplotype. There is also evidence
that the cyclooxygenase-2 enzyme encoded by PTGS2 has a
role in the pathogenesis of knee OA [119]. The
iodothyronine-deiodinase enzyme type 2 (DIO2) gene has
been identified as a new susceptibility locus for OA, using a
genome-wide linkage scan [120]. A meta-analysis of more
than 11,000 individuals provided evidence for an SNP in
GDF5 having a positive association with knee OA in both
European and Asian cohorts [121]. Other genes so far impli-
cated include the IL-1 gene cluster, matrilin-3 gene, IL-4 recep-
tor, frizzled-related protein-3 (FRZB) gene, metalloproteinase
gene ADAM12, and the asporin (ASPN) gene [122]. An
ambitious study that will screen over 8,000 people with hip or
knee OA and 6,000 healthy controls – arcOGEN (Arthritis
Research Campaign Osteoarthritis GENetics) [123] – has
been recently been announced and is likely to lead to the
identification of further genes associated with OA.
The Dutch GARP (Genetics, Arthrosis, and Progression)
study has shown that there is a moderate increased risk for
familial aggregation of both hand and hip OA whereas there
was no increased risk for knee OA [124]. That there should
be greater genetic effects on OA of the hand compared with
other sites is not surprising given the relatively weaker role for
environmental (including mechanical) factors. The familial risk
of hand OA has shown a moderate increase in risk in sisters
of women affected with hand OA and this risk was
substantially increased with the severity of the disease, with
sisters of those with severe first CMC OA having an RR of
6.9 [125]. Whole-genome linkage scans on female twins
have shown significant linkage of distal interphalangeal (DIP)
OA on chromosome 2 and Tot-KL (Kellgren-Lawrence score
for both hands) on chromosome 19 [126]. Polymorphisms in
the vitamin D receptor (VDR) gene have also been associated
with symmetrical hand OA, with a novel finding of a joint effect
of low calcium intake and VDR polymorphisms (aT haplotype)
having a moderate increased risk of symmetrical hand OA
[127]. Data from the Framingham Study have shown that
several chromosomes (DIP joint on chromosome 7, first CMC
joint on chromosome 15, and two sites in the female DIP joint
on chromosome 1 and first CMC joint on chromosome 20)
contain susceptibility genes for hand OA and that a joint-
specific approach rather than a global approach to hand OA
may be more useful in further investigations of these regions
[128]. Genome-wide scans have also revealed linkage peaks
on chromosomes 4q, 3p, and the short arm of chromosome 2
for idiopathic hand OA [129]. Genome-wide significance was
reached for a locus on chromosome 2 for first CMC and DIP
joints coinciding with the MATN3 gene, which encodes the
extracellular matrix protein, matrilin-3.
Gout
Environmental risk factors
Studies on environmental risk factors for gout have focused
mainly on the long-established risk factors of high purine diet
and diuretic use. The incidence of gout is increasing [130]
and high alcohol consumption is no longer the only risk factor
for the disease [131]. Other risk factors that have been
proposed include longevity, metabolic syndromes [132], and
use of certain pharmacologic agents [133]. The high
incidence in some ethnic groups has no obvious host factor,
and genetic factors may be implicated in these groups.
Dietary factors have a strong association with gout. Much of
the research in this area has been conducted by Choi and
colleagues [6,134-137]. As part of a large prospective study
in men (the Health Professionals Follow-up Study), a number
of factors were associated with an increased risk of gout.
Higher adiposity, hypertension, and diuretic use were all
moderate risk factors, whereas weight loss had a protective
role [136]. High intake of sugar-sweetened drinks and high
fructose intake from fruit juice and fruit have been associated
with a small increased risk of gout [137]. High meat intake
and seafood intake (purine intake) have also been positively
associated with gout with a small increase in risk [6]. In the
same study, long-term coffee consumption was inversely
associated with gout [138]. Consumption of low-fat dairy
products has been shown to decrease the risk of gout [6];
milk proteins (casein and lactalbumin) can reduce serum uric
acid levels in healthy individuals.
Genetic risk factors
Advances in the genetic factors behind gout have included a
variation in the SLC2A gene, which appears to make it more
difficult for uric acid to be removed from the blood [139]. A
polymorphism in the TNF-α promoter gene has been shown
to be significantly associated with gout [140]. Genetic
studies have included families with purine metabolism defects
and case-control studies of isolated aboriginal cohorts with
primary gout [133].
Fibromyalgia and chronic widespread pain
These poorly defined conditions are nonetheless the target of
many investigations seeking to unravel risk factors for their
causation or severity.
Environmental risk factors
Studies on environmental risk factors for FM and CWP have
focused on physical trauma and psychosocial factors.
Physical trauma in the months prior to disease onset has
been significantly associated with FM [141]. FM was found to
be 13 times more likely in patients who had a prior injury to
the cervical spine compared with those with injuries to the
lower extremities [142]. In a population-based prospective
study, three psychosocial factors independently predicted a
moderate increased risk of the development of CWP: somati-
sation, health-seeking behaviour, and poor sleep [143].
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There may be biologically based risk factors. Thus, abnor-
malities in the hypothalamic-pituitary-adrenal (HPA) stress-
response system may predict the onset of CWP. In a recent
study, high levels of cortisol after dexamethasone and high
levels in evening saliva moderately increased the risk of CWP
[144]. Low levels in morning saliva were also associated with
a small increase in risk. These factors were both independent
and additive predictors of CWP, with over 90% of new-onset
cases of CWP being identified by one or more of these HPA
factors.
Genetic risk factors
Perhaps surprisingly, there have been some interesting
suggestions of a genetic basis to FM. FM has been shown to
aggregate strongly in families: the odds of FM in a relative of
a proband with FM versus the odds of FM in a relative of a
proband with RA was 8.5 [145]. Genotypes in the promoter
region of the serotonin transporter gene (5-HTT) were
analysed in FM patients. A higher frequency of the S/S
genotype was found in patients compared with controls
[146], supporting the hypothesis of altered serotonin metabo-
lism in FM patients. Family studies have also shown
significant genetic linkage of the HLA region to FM [147].
Polymorphisms in the gene encoding the COMT (catechol-O-
methyltransferase) enzyme may also have a role in FM as
certain genotypes combined are higher in patients than
controls and a third genotype was significantly lower in
control groups [148].
Conclusions
Over the last 10 years, there have been some major
epidemiological advances, particularly in the field of genetic
risk factors, in which new candidate genes have been
identified and useful gene-environment interactions have
been studied. Studying lone environmental factors has been
less fruitful. The problem epidemiologically is that these
factors often explain only a small number of cases, and on
their own, they are not sufficient to cause the disease; both of
these issues present considerable epidemiological challen-
ges. The hope is that, as we begin to understand more about
the genetics behind the diseases and genetic studies
become more technically practical, it will enable stratification
by genetic subgroups to identify environmental triggers (such
as smoking). However, in other disease areas, progress has
been very slow and we still understand very little.
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